ABSTRACT Hemorrhage was prospectively identified in 26 of 116 consecutive patients (23%) who were receiving intracoronary streptokinase for occlusive coronary thrombi producing infarction. Bleeding was not influenced by the dose of streptokinase or the method of cardiac catheterization. Before treatment, prothrombin time and partial thromboplastin time were normal in both bleeders and nonbleeders. Fibrinogen levels measured by bioassay after streptokinase (mean + SEM) were 62 29 mg/dl in patients with major bleeding, 1 11 ±+ 26 mg/dl in patients with minor bleeding, and 109 + 13 mg/dl in nonbleeders (p -NS). The regression slope b calculated from poststreptokinase fibrinogen time-concentration data in 71 patients was 4.7 mg/dl/hr. However, mean fibrinogen concentrations calculated at sequential 5 hr intervals revealed no net regeneration for the first 20 hr after thrombolysis. The apparent fibrinogen regeneration rate was less than normal (31 mg/kg/day) for more than 10 hr but subsequently increased to 94 10 mg/kg/day by the second day. The initial apparent latency of fibrinogen regeneration paralleled the sharp rise in fibrinogen degradation products, which began to decline after 20 hr of treatment but remained elevated well into the second day. Because of their anticoagulant effects, these products may interfere with the fibrinogen assay, causing spuriously low results. Thus, whether the early delay in fibrinogen regeneration is real or simply a reflection of the effects of fibrinogen degradation products on the bioassay, it signals the time for caution in initiating systemic-heparin therapy.
son, even with relatively low doses of intracoronary streptokinse. 'l-' The occurrence of complicating hemorrhage has usually been associated with plasma proteolysis and a resulting lytic state characterized by a decrease in plasminogen, shortening of the whole blood euglobulin lysis time, a decrease in plasma-clottable protein (fibrinogen), the appearance of fibrinogen and fibrin degradation products (FDP-fdp), and prolongation of the prothrombin time and thrombin time. This may contribute to the dissolution of hemostatic plugs remote from coronary arterial thrombi. '6 On the other hand, we have found that the risk of hemorrhage is not a function of the success of thrombolysis or of its degree. 17 This is probably true because the degree of clot dissolution does not always parallel the extent of the lytic state resulting from the systemic effects of streptokinase. 18 19 Duckert et al. 20 stated that the lytic state, if severe, can contribute to hemorrhage; others have suggested that this may be caused by lysis of hemostatic plugs. 21 22 
THERAPY AND PREVENTION-THROMBOLYSIS
The anticoagulant activity of FDP-fdp has long been recognized. 23 25 Various fragments of FDP-fdp are known to interfere with thrombin activation, fibrin polymerization, and platelet function. 26 27 An electron microscopically indentifiable abnormality in clot structure has also been described,28 which apparently is caused by fragments of normal plasma protein that can alter the functional capacity of a fibrin clot and contribute to a hemorrhagic diathesis.
Thus the mechanisms of abnormal coagulation occurring with thrombolytic therapy are complex and as yet incompletely defined. For Vol. 69, No. 6, June 1984 once or twice daily for an additional 2 days. Plasma samples were sufficiently diluted (1:20) and additional thrombin was added as recommended by Morse et al .33 to override the spurious effects of therapeutically administered heparin. From 227 such determinations obtained from 71 patients (fibrinogen study group) in whom fibrinogen data were available for analysis, a time-concentration slope was computed. To further confirm the validity of these random observations, the time-concentration slope was recomputed from 73 data points obtained from 15 of the 71 patients in whom at least four serial measurements of poststreptokinase fibrinogen levels had been made. The apparent fibrinogen regeneration rate was estimated from 107 paired sequential samples obtained from 59 patients in the fibrinogen study group. In the latter analysis, fibrinogen regeneration rates were computed by an estimation of male and female blood volumes indexed to body weight34 and a ratio of total extra cellular-to-intravascular fibrinogen of 1. 
Results
Prevalence of bleeding. Bleeding was observed in 26 (23%) of 116 consecutive patients who were fastidiously monitored prospectively for this complication (table 1) . In nonbleeders mean fibrinogen levels before and the lowest levels estimated by bioassay after streptokinase were 281 ± 11 figure 1 ). These data were further analyzed by calculating the mean levels of fibrinogen measured in 5 hr cells for the first 55 hr after streptokinase administration (figure 2). Although fibrinogen levels remained above 100 mg/dl in many patients after treatment, the pooling of all data suggested an apparent latency in the restoration of fibrinogen levels lasting for at least 20 hr.
To test the accuracy of the fibrinogen time-concentration slope displayed in figure 1 , which was constructed from multiple random fibrinogen levels of various numbers per patient, a second time-concentration slope was calculated from a subset of 15 patients in whom at least four serial levels had been measured after the infusion of streptokinase at intervals of no less than 4 and usually 6 hr ( figure 3 ). The nearly identical slope b of 4.9 mg/dl/hr attests to the validity of figure  1 . A similar apparent latency of fibrinogen regeneration was identified in these patients (figure 4 figure 6 by a thirddegree polynomial curve of midrange data points because the Thrombo-Wellcotest yields range data rather than specific levels (<10, 10 to 40, and >40 ug/ml). This shows that these degradation products (the anti- FDP globulin used in the assay reacts primarily with the D and E fractions of the fibrinogen dimer) are most plentiful during the period when the apparent latency of fibrinogen regeneration is extant. Anticoagulation. The patients in this study were infused with heparin at the conclusion of the cardiac catheterization. However, recommendations have recently been made that the inauguration of anticoagulant therapy be delayed for several hours, even though no data exist on poststreptokinase fibrinogen or FDPfdp time-concentration curves. * On the other hand, the need for anticoagulation after streptokinase is recognized by all who use thrombolytic therapy, since the rethrombosis rate may exceed 15%. 17 Moreover, FDPfdp may paradoxically and unpredictably produce a state of hypercoagulability during which factor VIIIlike activity increases the amount of thrombin that is generated along with an increase in factor X. This may shift the balance of an unstable coagulation system toward further coagulation and extension of thrombosis. 24 Therefore, in spite of its risk, anticoagulation is essential.
Clinical implications. For several reasons, we suspect that the apparent latency of fibrinogen recovery may be an artifact reflecting the effects of FDP-fdp on the fibrinogen assay itself since the usually reported latency of fibrinogen regeneration after stimuli such as injury, trauma, or surgery is only an hour or two. 58, 58a, 58b, 59 Moreover, the production of FDP-fdp within minutes of administration of streptokinase would be expected to result in a positive feedback *Sherry S: Discussion of -intracardiac thrombolysis -treatment of myocardial infarction in the community hospital" presented at American College of Angiology, March 1982. mechanism (fractions D and E) on fibrinogen synthesis.60 Whether or not the initial flat (20 hr) portion of the poststeptokinase fibrinogen time-concentration curve is an artifact must await more precise methods of determining the effect of FDP-fdp on the bioassay of fibrinogen. Immunologic assays of fibrinogen and its soluble serum derivatives should shed further light on the extent and duration of fibrinolysis after streptokinase. In the meantime, a reasonable conclusion regarding the significance of the apparent latency of fibrinogen regeneration is that it reflects a sustained increase in circulating FDP-fdp. Because of their anticoagulant and antiplatelet effects, these degradation products may be troublesome in the presence of heparin therapy. Accordingly, consideration may be given to delaying the infusion of heparin until the effects of FDPfdp have begun to dissipate.
